Application of recombinant XVII type humanized collagen in treatment of cervical cancer

By recombining XVII humanized collagen, it inhibits the proliferation, migration and tumor-generating ability of cervical cancer cells, solves the problem of poor collagen water solubility in the prior art, provides a new idea for the treatment of cervical cancer, and demonstrates its in-cervical cancer Effectiveness and safety in cancer treatment.

CN118903389AActive Publication Date: 2024-11-08SHANXI JINBO BIO PHARMACEUTICAL CO LTD +1

Patent Information

Application Number
CN202411034354.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-08-01
Filing Date
2024-07-30
Publication Date
2024-11-08
Estimated Expiration
2044-07-30

AI Technical Summary

Technical Problem

The lack of effective biocompatible and biodegradable materials in existing cervical cancer treatment methods, especially the poor water-soluble collagen extracted from animals, limits its application in the treatment of cervical cancer, and there is no recombinant type XVII human source. Research on collagen in the treatment of cervical cancer.

Method used

Recombinant XVII humanized collagen is used to inhibit the proliferation, migration, invasion and tumor-generating ability of cervical cancer cells, and as a new drug preparation idea, it provides high biological activity and convenient preparation collagen materials.

Benefits of technology

It significantly inhibits the proliferation, migration and tumor-generating ability of cervical cancer cells, provides new ideas for cervical cancer treatment and drug preparation, and has clinical application potential due to its high biocompatibility and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903389A_ABST
    Figure CN118903389A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of biological medicine, particularly relates to application of recombinant XVII type humanized collagen in treatment of cervical cancer, and more particularly relates to application of the recombinant XVII type humanized collagen in preparation of medicine for preventing and / or treating cervical diseases. The recombinant XVII type humanized collagen comprises (A) a sequence shown in m or consists of the sequence shown in (A) m, wherein each A is an amino acid sequence selected from any one of SEQ ID No.1, SEQ ID No.2 and SEQ ID No.3; m is an integer between 1 and 10; wherein each A is the same or different, and two adjacent A are connected directly through a peptide bond or through more than one amino acid residue. Research data shows that the recombinant XVII type humanized collagen can significantly inhibit proliferation, migration, invasion and tumorigenesis capabilities of cervical cancer cells, and the inhibition effect has dose dependence.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Priority and related applications

[0002] This application claims the priority of the Chinese patent application filed with the China Patent Office on August 1, 2023, with application number 202310961277.X and invention name "Use of recombinant type XVII humanized collagen in the treatment of cervical cancer", the entire contents of which are incorporated by reference into this application. Technical Field

[0003] The present invention belongs to the field of biomedicine, and in particular relates to the use of recombinant humanized type XVII collagen in the treatment of cervical cancer. Background Art

[0004] Cervical cancer is the fourth most common cancer in women. In 2018, an estimated 570,000 women worldwide were diagnosed with cervical cancer, of which approximately 311,000 died. Cervical cancer develops in a woman's cervix (the entrance from the vagina to the uterus). Almost all cases of cervical cancer (99%) are associated with infection with high-risk human papillomavirus (HPV), a very common virus transmitted through sexual contact. Although most HPV infections resolve spontaneously without causing any symptoms, persistent infection can lead to cervical cancer. Currently, the methods that can effectively prevent most cases of cervical cancer mainly include primary prevention (HPV vaccination) and secondary prevention methods (screening and treatment of precancerous lesions).

[0005] Collagen is the most abundant protein in animals, accounting for about 30% of the total protein, and plays an important role in physiological processes such as cell adhesion. Due to its good biocompatibility and biodegradability, collagen has been widely used in the medical field. Up to now, most of the collagen used in various studies comes from animal tissues and skin extracts. However, collagen extracted from animals has poor water solubility and poor processability, which directly limits the development of many potential uses of collagen. Collagen produced by genetic engineering technology can effectively overcome the above shortcomings.

[0006] The Chinese patent application with application number 201911051106.3 and invention name “Human collagen type 17 polypeptide, production method and use thereof” records the recombinant type XVII humanized collagen previously studied and produced by the inventors of the present invention, and the recombinant type XVII humanized collagen has the characteristics of high water solubility and high biological activity. So far, there has been no report proposing the connection between recombinant type XVII humanized collagen and cervical cancer treatment. Summary of the invention

[0007] Problem that the invention aims to solve

[0008] The present invention intends to use the recombinant humanized type XVII collagen in the Chinese patent application with application number 201911051106.3 as raw material to evaluate its effectiveness in the treatment of cervical diseases such as cervical cancer. Specifically, the present invention intends to use recombinant humanized type XVII collagen to inhibit the proliferation, migration, invasion and tumor formation of cervical cancer cells, thereby achieving the effect of preventing and / or treating cervical cancer.

[0009] Solutions for solving problems

[0010] The present invention provides the use of recombinant humanized type XVII collagen in the preparation of a drug for preventing and / or treating cervical diseases; wherein:

[0011] The recombinant type XVII humanized collagen comprises or consists of the sequence shown in (A)m, wherein each A is an amino acid sequence selected from any one of SEQ ID No.1, SEQ ID No.2 and SEQ ID No.3, or an amino acid sequence in which one or more amino acid residues are substituted, added, inserted or deleted, or a sequence having at least 83% sequence identity with the amino acid sequence shown in any one of SEQ ID No.1, SEQ ID No.2 and SEQ ID No.3; m is an integer between 1 and 10; wherein each A is the same or different and two adjacent As are directly connected by a peptide bond or by one or more amino acid residues.

[0012] Furthermore, the recombinant humanized type XVII collagen comprises or consists of the amino acid sequence shown in SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, SEQ ID No.4 or SEQ ID No.5.

[0013] Furthermore, the cervical disease includes cervical cancer.

[0014] Furthermore, according to the pathological classification of cervical cancer, the cervical cancer includes squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma.

[0015] Furthermore, the recombinant humanized type XVII collagen prevents and / or treats cervical cancer by inhibiting the proliferation ability of cervical cancer cells, inhibiting the migration ability of cervical cancer cells, inhibiting the invasion ability of cervical cancer cells and / or inhibiting the tumor formation ability of cervical cancer cells.

[0016] Preferably, the recombinant humanized type XVII collagen prevents and / or treats cervical cancer by simultaneously inhibiting the proliferation ability, migration ability, invasion ability and tumor formation ability of cervical cancer cells.

[0017] Furthermore, the ability to inhibit the proliferation of cervical cancer cells includes inhibiting the DNA replication activity of cervical cancer cells.

[0018] Furthermore, the ability of inhibiting the tumorigenicity of cervical cancer cells includes inhibiting the ability of cervical cancer cells to form cell clones.

[0019] Furthermore, the ability to inhibit cervical cancer cells from forming cell clones includes inhibiting the number of cervical cancer cells forming cell clones and / or inhibiting the growth rate of cervical cancer cells.

[0020] Effects of the Invention

[0021] The present invention provides the use of recombinant humanized type XVII collagen in the preparation of drugs for preventing and / or treating cervical diseases. The research data of the present invention show that recombinant humanized type XVII collagen can significantly inhibit the proliferation, migration, invasion and tumor formation of cervical cancer cells, and the inhibitory effect has a certain dose dependence, thereby providing a new idea for the preparation of drugs for preventing and / or treating cervical diseases such as cervical cancer. In addition, since the collagen provided by the present invention is recombinant humanized type XVII collagen, it has the advantages of convenient preparation and high safety, thereby providing help for the preparation and application of drugs for cervical cancer and the clinical treatment of cervical cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 The statistical results show the effects of different concentrations of recombinant humanized type XVII collagen on the viability of cervical cancer cells at different time periods.

[0023] Figure 2 These are the test results of the effect of recombinant humanized type XVII collagen on the proliferation ability of cervical cancer cells.

[0024] Figure 3 These are the test results of the effect of recombinant humanized type XVII collagen on the migration ability of cervical cancer cells.

[0025] Figure 4 These are the test results of the effect of recombinant humanized type XVII collagen on the invasive ability of cervical cancer cells.

[0026] Figure 5 These are the test results of the effect of recombinant humanized type XVII collagen on the tumorigenicity of cervical cancer cells.

[0027] Figure 6 These are cervical cancer cell C33A tumor-bearing mice treated with recombinant humanized type XVII collagen and normal saline.

[0028] Figure 7 The results of tumor observation in mice bearing cervical cancer cells C33A treated with recombinant humanized type XVII collagen and normal saline.

[0029] Figure 8 The results of tumor volume detection in mice bearing cervical cancer cells C33A treated with recombinant humanized type XVII collagen and normal saline. DETAILED DESCRIPTION

[0030] Embodiments of the present invention will be described below, but the present invention is not limited thereto.

[0031] In the present invention, the word "may" includes both performing a certain process and not performing a certain process.

[0032] In the present invention, "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and the description includes instances where the event occurs and instances where it does not occur.

[0033] In the present invention, the terms "comprising", "having", "including" or "containing" may mean inclusive or open-ended, and do not exclude additional, uncited elements or method steps. At the same time, "comprising", "having", "including" or "containing" may also mean closed, excluding additional, uncited elements or method steps.

[0034] In the present invention, the references to "some specific / preferred embodiments", "other specific / preferred embodiments", "embodiments", etc., refer to specific elements (e.g., features, structures, properties and / or characteristics) related to the embodiments described herein, which are included in at least one embodiment described herein, and may or may not exist in other embodiments. In addition, it should be understood that the elements may be combined in various embodiments in any suitable manner.

[0035] In the present invention, a numerical range expressed using “a numerical value A to a numerical value B” or “a numerical value A-a numerical value B” means a range including the endpoints A and B.

[0036] In the present invention, the term "a" or "an" or "the" may mean "one", and may also mean "one or more", "at least one" and "one or more than one".

[0037] In the present invention, the term "individual", "patient" or "subject" includes mammals. Mammals include, but are not limited to, domestic animals (e.g., cows, sheep, cats, dogs and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats).

[0038] In the present invention, the term "working concentration" refers to the final concentration of a substance in a working system.

[0039] In the present invention, the term "treatment" means that after suffering from a disease, the subject is exposed to (e.g., administered) the recombinant humanized type XVII collagen described in the present invention, thereby alleviating the symptoms of the disease compared to when not exposed, and does not necessarily mean that the symptoms of the disease must be completely suppressed. Suffering from a disease means that the body has symptoms of the disease.

[0040] In the present invention, the term "prevention" means that before contracting the disease, by exposing the subject to the recombinant humanized type XVII collagen described in the present invention, the probability of contracting the disease and / or the symptoms after contracting the disease are reduced compared to when not in contact, and it does not mean that the disease must be completely suppressed.

[0041] In the present invention, the recombinant humanized type XVII collagen is recorded in the patent with application number 201911051106.3 and invention name “Human collagen type 17 polypeptide, its production method and use”.

[0042] In some embodiments, the recombinant type XVII humanized collagen described in the present invention comprises the sequence shown in (A)m or consists of the sequence shown in (A)m, wherein each A is an amino acid sequence selected from any one of SEQ ID No.1, SEQ ID No.2 and SEQ IDNo.3, or an amino acid sequence in which one or more amino acid residues are substituted, added, or deleted from any one of SEQ ID No.1, SEQ ID No.2 and SEQ IDNo.3, or a sequence having at least 83% sequence identity with the amino acid sequence shown in any one of SEQ ID No.1, SEQ ID No.2 and SEQ IDNo.3; m is an integer between 1 and 10; wherein each A is the same or different and two adjacent A's are directly connected by a peptide bond or by one or more amino acid residues.

[0043] The SEQ ID No.1, SEQ ID No.2 or SEQ ID No.3 described in the present invention is derived from the human type 17 collagen COL17A1 sequence. The human type 17 collagen COL17A1 sequence can be found at https: / / www.ncbi.nlm.nih.gov / protein / Q9UMD9.3.

[0044] SEQ ID No. 1: GSPGPKGDMGSPGPKGDRGFPGTPGIPGPLGHPGPQG PKGQKGSVGDPGMEGPMGQRGREGPMGPRGEA.

[0045] SEQ ID No. 2: GLQGLRGEVGLPGVKGDKGPMGPPGPKGDQGEKGPRGLTGEPGMRGLPGAVGEPGAKGAMGPA.

[0046] SEQ ID No. 3: GADFAGDLDYNELAVRVSESMQRQGLLQGMAYTVQ GPPGQPGPQGPPGISKVFSAYSNVTADLMDFFQTYGAIQGPPGQKGEMGT PGPKGDRGPAGPPGHPGPPGPRGHKGEKGDKGDQ.

[0047] In some specific embodiments, the recombinant humanized type XVII collagen described in the present invention comprises a sequence as shown in SEQ ID No.1, SEQ ID No.2 or SEQ ID No.3 or consists of a sequence as shown in SEQ ID No.1, SEQ ID No.2 or SEQ ID No.3.

[0048] In other specific embodiments, the recombinant humanized type XVII collagen of the present invention comprises or consists of the sequence shown in SEQ ID No. 4, which uses SEQ ID No. 1 as a repeating unit and is repeated 3 times.

[0049] SEQ ID No.4: GSPGPKGDMGSPGPKGDRGFPGTPGIPGPLGHPGPQG PKGQKGSVGDPGMEGPMGQRGREGPMGPRGEAGSPGPKGDMGSPGPKGDRGFPGTPGIPGPLGHPGPQGPKGQKGSVGDPGMEGPMGQRGREGPMGPRGEAGSPGPKGDMGSPGPKGDRGFPGTPGIPGPLGHPGPQGPKGQKGSVGDPGMEGPMGQRGREGPMGPRGEA.

[0050] In some other preferred embodiments, the recombinant humanized type XVII collagen of the present invention comprises or consists of the sequence shown in SEQ ID No.5, which uses SEQ ID No.2 as a repeating unit and is repeated 3 times.

[0051] SEQ ID No.5: GLQGLRGEVGLPGVKGDKGPMGPPGPKGDQGEKGP RGLTGEPGMRGLPGAVGEPGAKGAMGPAGLQGLRGEVGLPGVKGDKGPMGPPGPKGDQGEKGPRGLTGEPGMRGLPGAVGEPGAKGAMGPAGLQGLRGEVGLPGVKGDKGPMGPPGPKGDQGEKGPRGLTGEPGMRGLPGAVGEPGAKGAMGPA.

[0052] "Percent amino acid sequence identity" relative to a reference polypeptide sequence is defined as the percentage of amino acid residues in the candidate sequence that are identical to the amino acid residues in the reference polypeptide sequence, after the candidate sequence is aligned with the reference polypeptide sequence and, if necessary, spaces are introduced to obtain maximum percentage sequence identity, and any conservative substitutions are not considered as part of the sequence identity. Alignment for determining percentage amino acid sequence identity can be accomplished in various ways well known to those skilled in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithm required for achieving maximum alignment over the full length of the compared sequence.

[0053] Amino acid addition refers to adding amino acids to the C-terminus or N-terminus of an amino acid sequence, such as SEQ ID No.1, as long as the recombinant humanized type XVII collagen has the activity of the amino acid sequence of SEQ ID No.1.

[0054] Amino acid insertion refers to inserting an amino acid residue at an appropriate position of an amino acid sequence, such as SEQ ID No. 1. The inserted amino acid residues may be all or partly adjacent to each other, or the inserted amino acids may not be adjacent to each other, as long as the recombinant humanized type XVII collagen of the present invention retains the activity of the amino acid sequence of SEQ ID No. 1. In this context, the insertion position of the amino acid is preferably not between each repeating sequence.

[0055] Amino acid deletion means that 1, 2 or 3 or more amino acids can be deleted from an amino acid sequence, such as the sequence of SEQ ID No. 1, as long as the recombinant humanized type XVII collagen of the present invention retains the activity of the amino acid sequence of SEQ ID No. 1.

[0056] Amino acid substitution refers to the replacement of an amino acid residue at a certain position in an amino acid sequence, such as SEQ ID No. 1, with another amino acid residue, as long as the recombinant humanized type XVII collagen of the present invention retains the activity of the amino acid sequence of SEQ ID No. 1.

[0057] In the present invention, the substitution may be a conservative amino acid substitution, for example, compared with the amino acid sequence of SEQ ID No. 1, 3, preferably 2 or 1 amino acids are replaced by amino acids with similar or similar properties to form a peptide. These conservative variant peptides can be generated by amino acid substitution according to Table 1.

[0058] Table 1 Conservative substitution of amino acids

[0059] Initial residue Representative replacement Preferred substitutions Ala(A) Val; Leu; Ile Val Arg(R) Lys; Gln; Asn Lys Asn(N) Gln; His; Lys; Arg Gln Asp(D) Glu Glu Cys(C) Ser Ser Gln(Q) Asn Asn Glu(E) Asp Asp Gly(G) Pro; Ala Ala His(H) Asn; Gln; Lys; Arg Arg Ile(I) Leu; Val; Met; Ala; Phe Leu Leu(L) Ile; Val; Met; Ala; Phe Ile Lys(K) Arg; Gln; Asn Arg Met(M) Leu; Phe; Ile Leu Phe(F) Leu; Val; Ile; Ala; Tyr Leu Pro(P) Ala Ala Ser(S) Thr Thr Thr(T) Ser Ser Trp(W) Tyr; Phe Tyr Tyr(Y) Trp; Phe; Thr; Ser Phe Val(V) Ile; Leu; Met; Phe; Ala Leu

[0060] All amino acids in the amino acid sequence of the present invention may be L-type amino acids, and one or more (such as 2-5, 2-4 or 2-3) of the amino acids may also be replaced with amino acids with D-type conformation, artificially modified amino acids, rare amino acids existing in nature, etc., to improve the bioavailability, stability and / or antiviral activity of the polypeptide. Among them, D-type amino acids refer to amino acids corresponding to L-type amino acids constituting proteins; artificially modified amino acids refer to common L-type amino acids constituting proteins that have been modified by methylation, phosphorylation, etc.; rare amino acids existing in nature include uncommon amino acids constituting proteins and amino acids that do not constitute proteins, such as 5-hydroxylysine, methylhistidine, γ-aminobutyric acid, homoserine, etc.

[0061] In the present invention, recombinant humanized type XVII collagen can be produced by conventional methods in the art. Exemplarily, it can be produced by the following steps: ① construction of genetically engineered Escherichia coli; ② fermentation culture of genetically engineered Escherichia coli; ③ induction and expression of recombinant humanized type XVII collagen; and ④ purification and optional enzyme cleavage of recombinant human collagen.

[0062] Unless otherwise defined, other technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0063] Example

[0064] The present invention is further illustrated by the following examples, but any example or combination thereof should not be construed as limiting the scope or implementation of the present invention. The scope of the present invention is defined by the appended claims. In combination with this specification and common knowledge in the art, a person of ordinary skill in the art can clearly understand the scope defined by the claims. Without departing from the spirit and scope of the present invention, a person of ordinary skill in the art can make any modification or change to the technical solution of the present invention, and such modification and change are also included in the scope of the present invention.

[0065] In the examples, if the specific conditions are not specified, the conditions are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for all reagents or instruments, they are all conventional products that can be purchased commercially. In order to better illustrate the present invention, numerous specific details are provided in the specific embodiments below. It should be understood by those skilled in the art that the present invention can be implemented equally without certain specific details. In other embodiments, methods, means, equipment and steps well known to those skilled in the art are not described in detail to highlight the purport of the present invention.

[0066] The amino acid sequence of the recombinant humanized type XVII collagen used in the examples is shown in SEQ ID No.1.

[0067] Example 1: Effect of recombinant humanized type XVII collagen on the growth and proliferation of cervical cancer cells

[0068] (1) CCK-8 experiment:

[0069] After setting up experimental groups (experimental group: cervical cancer cells (human cervical squamous cell carcinoma cell Siha) + 10% FBS culture medium + recombinant type XVII humanized collagen; negative control group: cervical cancer cells (Siha) + 10% FBS culture medium, no collagen co-culture; blank control group: no cells, 10% FBS culture medium, no collagen co-culture), cells of appropriate density were inoculated in a 96-well plate as needed, with a volume of 100 μL / well; 3-5 replicate wells were set up for each group. The 96-well culture plate was placed in a cell culture incubator and pre-cultured for 6-8 hours at 37°C and 5% CO2. After the cells adhered to the wall, recombinant type XVII humanized collagen was added to the experimental group, and the working concentrations were 0 mg / mL (negative control group), 0.5 mg / mL, 1 mg / mL, 4 mg / mL and 8 mg / mL, respectively. After the cells were co-cultured with collagen for 24 h, 48 h, and 72 h, the 96-well plate was transferred to the clean bench in the cell room, the culture medium was discarded, the residual liquid was aspirated, and the plate was protected from light. 100 μL of serum-free culture medium (from Sigma) and 10 μL of CCK-8 (from GK10001, GLPBIO) were added to each well, and PBS was added to the periphery of the 96-well plate to prevent the volatilization of the reagent. The 96-well plate was placed in a 37°C incubator and cultured for 1 hour in the dark, and the absorbance value OD was measured using an enzyme marker. 450 The measurement was repeated 3 times to obtain the average value. The cell survival rate was calculated according to the formula in the kit instructions: (OD value of the experimental group - OD value of the blank control group) / (OD value of the negative control group - OD value of the blank control group) × 100%.

[0070] (2) Edu proliferation assay:

[0071] Cultivate cervical cancer cells: Take Siha cells in the logarithmic growth phase, inoculate about 2000 cells per well in a 96-well plate, put it in a cell culture incubator, and culture it to the normal growth stage. Then use a pipette to add the cell suspension to the 96-well plate, and add 100 μL of the corresponding cell suspension to each well. Set up 3-5 replicates for each group. Place the 96-well culture plate in a cell culture incubator and pre-culture for 6-8 hours at 37°C and 5% CO2. After the cells adhere, add fresh culture medium (from Sigma) to the control group, and add an equal volume of fresh culture medium and recombinant type XVII humanized collagen (working concentration is 8 mg / mL) to the experimental group, and incubate for 72 hours. EdU solution (from C0075, Beyotime) was diluted with DMEM medium containing 10% fetal bovine serum at a ratio of 1000:1. 100 μL of the prepared medium containing EdU solution was added to each well, and the cells were placed in a cell culture incubator for 2 hours, and then the medium was discarded; the cells were then washed twice with PBS, each for 5 minutes; cells were fixed: 100 μL of cell fixative containing 4% (W / V) paraformaldehyde (from P0099, Beyotime) was added to each well, incubated at room temperature for 10 minutes, and then the fixative was poured out. 100 μL of glycine with a concentration of 2 mg / mL was added to each well, and after incubation on a shaker for 5 minutes, the glycine solution was poured out. 100 μL of PBS was added to each well, and then the cells were washed on a decolorizing shaker for 5 minutes, and the PBS was discarded. 100 μL of PBS containing 0.5% (V / V) TritonX-100 was added to each well, and then incubated on a decolorizing shaker for 10 minutes, and then washed twice with PBS for 5 minutes each time; Apollo staining: 100 μL of Apollo staining reaction solution (derived from CA1170, Solarbio) was added to each well, incubated at room temperature in the dark for 30 minutes, and then 100 μL of permeabilization agent containing 0.5% (V / V) TritonX-100 (derived from P0096, Beyotime) was added, and then washed three times; DNA staining: According to the instructions of the kit, DNA concentration stain (derived from C1029, Beyotime) was diluted with double distilled water at a ratio of 50:1, and an appropriate amount of 1×Hoechst33342 DNA staining solution was prepared, and then stored in the dark. 200 μL of 1×Hoechst33342 DNA staining solution was added to each well, incubated at room temperature in the dark for 20 minutes, and then the staining reaction solution was discarded. Then, 100 μL PBS was added to each well for three washes. Photographs were taken under a fluorescence microscope. Hoechst 33342 was blue fluorescence with a maximum excitation wavelength of 346 nm and a maximum emission wavelength of 460 nm. Counting was performed and the results were analyzed.

[0072] Experimental results:

[0073] The results of CCK-8 assay are as follows Figure 1 As shown, the results of the Edu proliferation experiment are as follows Figure 2 As shown in the figure, the results of CCK-8 and Edu proliferation experiments showed that the use of recombinant humanized collagen type XVII to treat cervical cancer cells for 72 hours can significantly inhibit the growth of tumor cells, and as the concentration of collagen increases, the inhibitory effect also increases significantly; after group culture, compared with the control group, the cervical cancer cells in proliferation activity after treatment with recombinant humanized collagen type XVII ( Figure 2 The proportion of Edu red fluorescent cells was significantly decreased, indicating that recombinant type XVII humanized collagen had an inhibitory effect on the DNA replication activity and proliferation of cervical cancer cells.

[0074] Example 2: Effect of recombinant humanized type XVII collagen on the migration ability of cervical cancer cells Scratch assay:

[0075] First, use a marker to draw a straight line on the back of the six-well plate; inoculate an appropriate amount of cervical cancer cell Siha into the six-well plate, and the inoculation amount is appropriate to cover the bottom of the plate after the cells adhere to the wall. After the cells adhere to the wall, add serum-free medium to the control group, and add an equal volume of recombinant type XVII humanized collagen (working concentration is 8 mg / mL) mixed with serum-free medium to the experimental group; after the cells cover the bottom of the plate, use a 10-microliter pipette tip to scratch the cells perpendicular to the well plate, and try to ensure that the width of each scratch is consistent; pour out the cell culture medium, rinse the well plate three times with PBS, try to remove the cell debris produced by the scratch, and take pictures under an inverted microscope, which is recorded as the scratch width at 0 hours. Put it in a cell incubator and take pictures again after 24 hours.

[0076] Experimental results:

[0077] The experimental results are as follows Figure 3 As shown, it can be seen that after cervical cancer cells were treated with recombinant humanized type XVII collagen, the cell migration ability was significantly weakened compared with the control group without collagen treatment.

[0078] Example 3: Effect of recombinant humanized type XVII collagen on the invasive ability of cervical cancer cells

[0079] Transwell chamber invasion assay:

[0080] Before the experiment, the cervical cancer cells Siha were starved for 24 hours by replacing serum-free medium to eliminate the influence of serum on the experiment. The cells were digested, centrifuged at 1000 rpm for 5 minutes, the supernatant was poured out, and the cells were resuspended in serum-free medium to adjust the cell concentration to 2×10 4In the control group, 500 μL of DMEM medium containing 10% fetal bovine serum was added to the lower chamber, and in the experimental group, an equal volume of DMEM medium containing 10% fetal bovine serum was added to the lower chamber, mixed with recombinant humanized collagen type XVII (working concentration was 8 mg / mL), and then placed in a Transwell chamber (724101, NEST), avoiding bubbles from forming on the contact surface between the chamber bottom and the culture medium, and adding 5×10 4 cells and place them in a cell culture incubator for further culture for 48 hours. Take out the chamber, wipe off the cells inside the chamber with a cotton swab, and keep the cells on the outer side of the chamber. Then fix with 4% (W / V) paraformaldehyde for 10 minutes. Stain with hematoxylin for 10 minutes and rinse with tap water for 5 minutes to ensure that there is no hematoxylin staining in the chamber. Bake the chamber in an oven to dry, and then use a blade to cut the membrane along the edge of the chamber. Add a drop of neutral gum on a clean slide, with the cell side facing down, then cover with a coverslip and gently press out the excess neutral gum. Observe and count under a microscope. Randomly select 5 fields of view (top, bottom, left, right and middle) under a microscope to count the number of cells.

[0081] Experimental results:

[0082] The experimental results are as follows Figure 4 As shown, after cervical cancer cells were treated with recombinant humanized type XVII collagen, the invasion ability of tumor cells in the experimental group was significantly weakened compared with the control group without collagen treatment.

[0083] Example 4: Effect of recombinant humanized type XVII collagen on the tumorigenicity of cervical cancer cells Clone formation experiment:

[0084] Take cervical cancer cells Siha in the logarithmic growth phase, digest them conventionally, centrifuge and collect the cell pellet; resuspend the cell pellet, count the cells, and adjust the cell concentration to 1×10 5 / mL, diluted to 1×10 3 / mL; take 200μL of cell suspension and inoculate the plate (i.e., 200 cells are inoculated in each plate), add culture medium to 10mL, of which the control group adds culture medium, and the experimental group adds an equal volume of recombinant type XVII humanized collagen (working concentration is 8mg / mL) mixed with culture medium; shake in a "cross" shape to evenly disperse the cells, put them in an incubator for routine culture for 2-3 weeks; terminate the culture when visible clones appear, and discard the culture medium; wash with PBS twice; fix with 5mL of methanol for 15min, and discard the fixative; add Giemsa stain (C0131, Beyotime) for staining for 20min, rinse with tap water, air dry, and take pictures.

[0085] Experimental results:

[0086] The experimental results are as follows Figure 5As shown, after cervical cancer cells were treated with recombinant humanized type XVII collagen, the cells grew slowly and the number of clones formed was significantly less than that of the control group without collagen treatment.

[0087] Collagen is an important component of the extracellular matrix, and its structure and function are complex. At present, relevant studies have shown that collagen plays a role in the tumor microenvironment. Recombinant humanized collagen may achieve a tumor suppressor effect by remodeling the tumor microenvironment. The research of the present invention proves that recombinant type XVII humanized collagen has an inhibitory effect on the proliferation, migration, invasion and tumor formation of cervical cancer cells, and the inhibitory effect on its proliferation, migration, invasion and tumor formation is more significant at high concentrations. This will provide a new theoretical basis and support for the clinical treatment of cervical cancer and drug development.

[0088] Example 5: Effect of recombinant humanized type XVII collagen on the tumorigenicity of cervical cancer cells Subcutaneous tumorigenicity animal experiment in nude mice:

[0089] (1) Preparation: Prepare tumor cells (cervical cancer cell C33A) in logarithmic phase growth with a cell density of about 80-90%.

[0090] (2) Cell collection: discard the old culture medium, wash the cells 1-2 times with PBS (to remove the serum in the cells), use trypsin to digest the cells, prepare a cell suspension, centrifuge, remove the supernatant, then resuspend the cells with PBS or serum-free culture medium and count the cells to calculate the required final concentration. Usually, the amount of cells used for subcutaneous tumor inoculation is (1-5)×10 6 cells, the inoculation volume is 0.1 mL, so the concentration of cervical cancer cell C33A is about (1-5)×10 7 cells / mL.

[0091] (3) Nude mouse inoculation: Take 10 female nude mice aged 4 to 6 weeks and mark them with ear tags. After 3 days of feeding in an SPF environment, fix the nude mice with the left hand and perform subcutaneous injection at the root of the left thigh. During the injection, insert the needle about 1 cm into the subcutaneous tissue, and the injection volume is 100 μl. During the inoculation process, the cell suspension should be placed on ice to slow down cell apoptosis. The body weight and tumor volume (length × width) of the nude mice were measured every week. 2 ÷2).

[0092] (4) Drug injection: 3-5 days after the tumor cells were injected, the subcutaneous tumor volume markers of each nude mouse were checked and randomly divided into 2 groups, a control group (NC) of 5 mice and an experimental group (rhCOL17) of 5 mice for biological replicates. Each mouse in the control group was given an intraperitoneal injection of 100 μl of normal saline, and each mouse in the experimental group was given an intraperitoneal injection of 100 μl of recombinant type XVII humanized collagen (concentration of 8 mg / ml) dissolved in normal saline. The drug was injected once every 3 days, for a total of 7 times. During this period, the body weight and tumor volume (length × width) of the nude mice were regularly monitored. 2 ÷2).

[0093] (5) Sacrifice: According to the experimental design, the tumor volume did not exceed 1000mm 3 Previously, nude mice needed to be euthanized, and the tumors removed about 21 days later for photographic measurement.

[0094] Experimental results:

[0095] The experimental results are as follows Figures 6 to 8 As shown, cervical cancer cell C33A can form tumors in nude mice. After intraperitoneal injection of recombinant humanized collagen type XVII, the tumor volume is significantly smaller than that of the control group injected with normal saline. This proves that recombinant humanized collagen type XVII has a significant inhibitory effect on the tumorigenicity of cervical cancer cells.

Claims

1. Use of recombinant humanized type XVII collagen in the preparation of a drug for preventing and / or treating cervical diseases; wherein: The recombinant type XVII humanized collagen comprises or consists of the sequence shown in (A)m, wherein each A is an amino acid sequence selected from any one of SEQ ID No.1, SEQ ID No.2 and SEQ ID No.3, or an amino acid sequence in which one or more amino acid residues are substituted, added, inserted or deleted, or a sequence having at least 83% sequence identity with the amino acid sequence shown in any one of SEQ ID No.1, SEQ ID No.2 and SEQ ID No.3; m is an integer between 1 and 10; wherein each A is the same or different and two adjacent As are directly connected by a peptide bond or by one or more amino acid residues.

2. The use according to claim 1, characterized in that The recombinant humanized type XVII collagen comprises or consists of the amino acid sequence shown in SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, SEQ ID No.4 or SEQ ID No.

5.

3. The use according to claim 1 or 2, characterized in that: The cervical disease includes cervical cancer.

4. The use according to claim 4, characterized in that The cervical cancer includes squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma.

5. The use according to claim 3 or 4, characterized in that: The recombinant humanized type XVII collagen prevents and / or treats cervical cancer by inhibiting the proliferation ability, migration ability, invasion ability and / or tumor formation ability of cervical cancer cells.

6. The use according to claim 5, characterized in that The ability to inhibit the proliferation of cervical cancer cells includes inhibiting the DNA replication activity of cervical cancer cells.

7. The use according to claim 5, characterized in that The inhibiting the tumorigenicity of cervical cancer cells includes inhibiting the ability of cervical cancer cells to form cell clones.

8. The use according to claim 7, characterized in that The ability to inhibit cervical cancer cells from forming cell clones includes inhibiting the number of cervical cancer cells forming cell clones and / or inhibiting the growth rate of cervical cancer cells.

Citation Information

Patent Citations

  • Human collagen 17-type polypeptide and production method and application thereof

    CN110845603A

  • Application of recombinant XVII type humanized collagen in breast cancer treatment

    CN116270982A

  • Recombinant human type xvii collagen, and preparation method and use thereof

    US20230119018A1

Cited By

  • Anti-HPV (human papillomavirus) infection recombinant III-type human collagen peptide as well as preparation method and application thereof

    CN119306819A

  • Recombinant human collagen type III peptide against HPV infection and preparation method and application thereof

    CN119306819B

  • New application of recombinant XVII type humanized collagen

    CN119548617A

  • New applications of recombinant humanized type XVII collagen

    CN119548617B

  • Application of recombinant III-type humanized collagen in treatment of cervical cancer

    CN119564836A